Professor Bertrand Cariou
Thorax institute, INSERM UMR 1087, CHU Nantes, Nantes (France)
Open-label ODYSSEY APPRISE study: interim data from the first 843 participants
Event: ESC Congress 2017
Topic: Lipids (Epidemiology and Prevention)
Session: Lipids
Are there effects of PCSK9 inhibitors beyond cholesterol lowering?
Event: ESC Congress 2017
Topic: Lipids
Session: PCSK9 inhibition - cholesterol reduction and beyond
ESC 365 is supported by
